Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Current Hematologic Malignancy Reports|March 2, 2011
Chronic myelogenous leukemia: monitoring response to therapySusan Branford, Jodi Prime
Methods in Molecular Medicine|March 1, 2006
Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCRSusan Branford, Timothy Hughes
Methods in Molecular Medicine|March 1, 2006
Detection of BCR-ABL mutations and resistance to imatinib mesylateSusan Branford, Timothy Hughes
Blood Reviews|January 24, 2006
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemiaTimothy Hughes, Susan Branford
Current Hematologic Malignancy Reports|November 8, 2019
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Naranie Shanmuganathan, Susan Branford
British Journal of Haematology|June 14, 2021
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencingNaranie Shanmuganathan, Susan Branford
Seminars in Hematology|June 5, 2003
Molecular monitoring of chronic myeloid leukemiaTim Hughes, Susan Branford
Hematology. American Society of Hematology. Education Program|December 13, 2012
Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?David T Yeung, Susan Branford
Current Opinion in Hematology|January 20, 2011
Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Monitoring disease response to tyrosine kinase inhibitor therapy in CMLTimothy P Hughes, Susan Branford
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Current Hematologic Malignancy Reports|March 2, 2011
Chronic myelogenous leukemia: monitoring response to therapySusan Branford, Jodi Prime
Methods in Molecular Medicine|March 1, 2006
Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCRSusan Branford, Timothy Hughes
Methods in Molecular Medicine|March 1, 2006
Detection of BCR-ABL mutations and resistance to imatinib mesylateSusan Branford, Timothy Hughes
Blood Reviews|January 24, 2006
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemiaTimothy Hughes, Susan Branford
Current Hematologic Malignancy Reports|November 8, 2019
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Naranie Shanmuganathan, Susan Branford
British Journal of Haematology|June 14, 2021
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencingNaranie Shanmuganathan, Susan Branford
Seminars in Hematology|June 5, 2003
Molecular monitoring of chronic myeloid leukemiaTim Hughes, Susan Branford
Hematology. American Society of Hematology. Education Program|December 13, 2012
Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?David T Yeung, Susan Branford
Current Opinion in Hematology|January 20, 2011
Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Monitoring disease response to tyrosine kinase inhibitor therapy in CMLTimothy P Hughes, Susan Branford
Pageof 14